Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 5,469 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumor Malignancies, Cancer Clear all

Conditions: Advanced Solid Tumors
Interventions: axitinib, crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 15
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions: Metformin, Simvastatin, Digoxin; Drug
Lead sponsor: Danae Hamouda, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami Beach, Florida • Kansas City, Missouri

Conditions: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
Interventions: 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors; Diagnostic Test
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more

Conditions: Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
Interventions: Lymphodepletion, TCR-T cells (MDG1015); Drug · Biological
Lead sponsor: Medigene AG; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2042
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym022; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Grand Rapids, Michigan • Houston, Texas

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Educational Cancer Intervention, ICF Text Version 1, ICF Text Version 2, ICF Video Version 1, ICF Video Version 2, ICF Video Version 3, ICF Video Version 4, Survey Administration; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Interventions: MX006; Drug
Lead sponsor: Myricx Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Sarasota, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Cancer, Small Cell Lung Cancer
Interventions: Ganetespib, Doxorubicin; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: cancer prevention intervention, educational intervention; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 2,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 19
States / cities: Long Beach, California • Farmington, Connecticut • Fort Myers, Florida + 16 more

Conditions: Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions: Levetiracetam (Keppra); Drug
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: IMGN388; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Fort Myers, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Interventions: AGX101; Drug
Lead sponsor: Angiex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Sarasota, Florida • St Louis, Missouri + 4 more

Conditions: KRAS p.G12C Mutant Advanced Solid Tumors
Interventions: sotorasib, Anti PD-1/L1, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 39
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 29 more

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Advanced Cancer
Interventions: FP-1039; Drug
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Advanced Malignant Solid Tumors
Interventions: MLN7243; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Boston, Massachusetts • St Louis, Missouri • Cleveland, Ohio + 4 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Communication Intervention, Questionnaire Administration, Waiting List; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Medical Chart Review; Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 2,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 630
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: oxaliplatin; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 6 more

Conditions: Advanced Malignant Solid Tumors
Interventions: PM02734 and erlotinib, Erlotinib; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Interventions: PLX038, Rucaparib, Ondansetron; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Community Enhanced Virtual Informed Consent

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Registration and Informed Consent Study for the Childhood Cancer Research Network

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Safety Study of FP-1039 To Treat Cancer

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers